MicroRNAs and liver cancer associated with iron overload: Therapeutic targets unravelled

World Journal of Gastroenterology

Volumn 19, Issue 32, 2013, Pages 5212-5226

  Greene, Catherine M ^a   Varley, Robert B ^b   Lawless, Matthew W ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Hepatitis C; Iron regulation; Liver cancer; MicroRNAs; Therapeutic targets

Indexed keywords

FERRITIN; MICRORNA; MICRORNA 122; MICRORNA 200B; TRANSFERRIN;

APOPTOSIS; CANCER GROWTH; CELL CYCLE PROGRESSION; HOMEOSTASIS AND REGULATION; HUMAN; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER REGENERATION; METASTASIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; STELLATE CELL; TUMOR INVASION; ANIMAL; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DIAGNOSTIC USE; DISEASE COURSE; GENE THERAPY; GENETIC SCREENING; GENETICS; LIVER; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; SECONDARY;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; GENETIC TESTING; GENETIC THERAPY; HUMANS; IRON OVERLOAD; LIVER; LIVER NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS;

EID: 84882939134     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i32.5212     Document Type: Review

References (168)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687 [PMID: 16929323]
2. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371-1383 [PMID; 22314424 DOI: 10.1016/j.jhep.2011.11.026]
3. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v [PMID: 15831268]
4. Lawless MW, Mankan AK, Gray SG, Norris S. Endoplasmic reticulum stress--a double edged sword for Z alpha-1 antitrypsin deficiency hepatoxicity. Int J Biochem Cell Biol 2008; 40: 1403-1414 [PMID: 18353704 DOI: 10.1016/ j.biocel.2008.02.008]
5. Lawless MW, Greene CM, Mulgrew A, Taggart CC, O'Neill SJ, McElvaney NG. Activation of endoplasmic reticulumspecific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol 2004; 172: 5722-5726 [PMID: 15100318]
6. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226]
7. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063 [PMID: 19003900 DOI: 10.1002/hep.22580]
8. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205 [PMID: 17506695]
9. Zhang B, Wang Q, Pan X. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol 2007; 210: 279-289 [PMID: 17096367]
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233 [PMID: 19167326 DOI: 10.1016/j.cell.2009.01.002]
11. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-1934 [PMID: 18048652]
12. Liu J, Rivas FV, Wohlschlegel J, Yates JR, Parker R, Hannon GJ. A role for the P-body component GW182 in microRNA function. Nat Cell Biol 2005; 7: 1261-1266 [PMID: 16284623]
13. Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J 2012; 18: 215-222 [PMID; 22647357 DOI: 10.1097/PPO.0b013e318250c001]
14. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci USA 2007; 104: 9667-9672 [PMID: 17535905]
15. Moretti F, Thermann R, Hentze MW. Mechanism of translational regulation by miR-2 from sites in the 5' untranslated region or the open reading frame. RNA 2010; 16: 2493-2502 [PMID: 20966199 DOI: 10.1261/rna.2384610]
16. Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-471 [PMID: 18498749 DOI: 10.1016/j.molcel.2008.05.001]
17. Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, Jin Y. miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One 2010; 5: e9429 [PMID; 20195546 DOI: 10.1371/journal.pone.0009429]
18. Beitzinger M, Meister G. Preview. MicroRNAs: from decay to decoy. Cell 2010; 140: 612-614 [PMID: 20211130 DOI: 10.1016/j.cell.2010.02.020]
19. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA. org resource: targets and expression. Nucleic Acids Res 2008; 36: D149-D153 [PMID: 18158296]
20. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105 [PMID: 18955434 DOI: 10.1101/ gr.082701.108]
21. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500 [PMID: 15806104]
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20 [PMID: 15652477]
23. Nahon P, Ganne-Carrié N, Trinchet JC, Beaugrand M. Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis. Gastroenterol Clin Biol 2010; 34: 1-7 [PMID; 19762191 DOI: 10.1016/j.gcb.2009.07.032]
24. Kew MC. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett 2009; 286: 38-43 [PMID: 19081672 DOI: 10.1016/j.canlet.2008.11.001]
25. Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in hemochromatosis. Observations in 163 patients. Ann N Y Acad Sci 1988; 526: 245-257 [PMID: 3389643]
26. Bothwell TH, Bradlow BA. Siderosis in the Bantu. A combined histopathological and chemical study. Arch Pathol 1960; 70: 279-292 [PMID: 13803127]
27. Bothwell TH, Isaacson C. Siderosis in the bantu. A comparison of incidence in males and females. Br Med J 1962; 1: 522-524 [PMID: 13871675]
28. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256-1262 [PMID: 4058506]
29. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995; 60: 160-162 [PMID: 7829208]
30. Purtilo DT, Gottlieb LS. Cirrhosis and hepatoma occurring at Boston City Hospital (1917-1968). Cancer 1973; 32: 458-462 [PMID: 4353016]
31. MacSween RN, Scott AR. Hepatic cirrhosis: a clinico-pathological review of 520 cases. J Clin Pathol 1973; 26: 936-942 [PMID: 4784502]
32. Blumberg RS, Chopra S, Ibrahim R, Crawford J, Farraye FA, Zeldis JB, Berman MD. Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis. Gastroenterology 1988; 95: 1399-1402 [PMID: 2844622]
33. Deugnier Y, Turlin B, Loréal O. Iron and neoplasia. J Hepatol 1998; 28 Suppl 1: 21-25 [PMID: 9575445]
34. Goh J, Callagy G, McEntee G, O'Keane JC, Bomford A, Crowe J. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of literature. Eur J Gastroenterol Hepatol 1999; 11: 915-919 [PMID: 10514128]
35. Köhler HH, Höhler T, Küsel U, Kirkpatrick CJ, Schirmacher P. Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report. Pathol Res Pract 1999; 195: 509-513 [PMID: 10448668]
36. Pellisé M, González-Abraldes J, Navasa M, Miquel R, Bruguera M. [Hepatocellular carcinoma in a patient with hereditary hemochromatosis without cirrhosis]. Gastroenterol Hepatol 2001; 24: 132-134 [PMID: 11261224]
37. Britto MR, Thomas LA, Balaratnam N, Griffiths AP, Duane PD. Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis. Scand J Gastroenterol 2000; 35: 889-893 [PMID: 10994630]
38. Gray SG, Crowe J, Lawless MW. Hemochromatosis: as a conformational disorder. Int J Biochem Cell Biol 2009; 41: 2094-2097 [PMID: 19375516 DOI: 10.1016/j.biocel.2009.04.006]
39. Ryan JD, Ryan E, Fabre A, Lawless MW, Crowe J. Defective bone morphogenic protein signaling underlies hepcidin deficiency in HFE hereditary hemochromatosis. Hepatology 2010; 52: 1266-1273 [PMID: 20658468 DOI: 10.1002/ hep.23814]
40. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33: 647-651 [PMID: 11230745]
41. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Both-well TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996; 87: 3470-3476 [PMID: 8605366]
42. Moyo VM, Makunike R, Gangaidzo IT, Gordeuk VR, McLaren CE, Khumalo H, Saungweme T, Rouault T, Kiire CF. African iron overload and hepatocellular carcinoma (HA-7-0-080). Eur J Haematol 1998; 60: 28-34 [PMID: 9451425]
43. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, Kew MC. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998; 27: 1563-1566 [PMID: 9620327]
44. Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, Siziba K. Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology 2006; 219: 41-52 [PMID: 16337327]
45. Asare GA, Paterson AC, Kew MC, Khan S, Mossanda KS. Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J Pathol 2006; 208: 82-90 [PMID: 16278820]
46. Barry M, Scheuer PJ, Sherlock S, Ross CF, Williams R. Hereditary spherocytosis with secondary haemochromatosis. Lancet 1968; 2: 481-485 [PMID: 4174505]
47. Chung H, Kudo M, Kawasaki T, Kitano M, Minami Y, Suetomi Y, Onda H. Hepatocellular carcinoma associated with secondary haemochromatosis in non-cirrhotic liver: a case report. Hepatol Res 2003; 26: 254-258 [PMID: 12850700]
48. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124: 114-117 [PMID: 14675416]
49. Wang Q, Liu Y, An D, Diao H, Xu W, He X, Sun R, Wei L, Li L. Regulation of hepatitis C virus translation initiation by iron: role of eIF3 and La protein. Virus Res 2012; 167: 302-309 [PMID: 22634302 DOI: 10.1016/j.virusres.2012.05.014]
50. Liu Y, An D, Sun R, Jin L, Wang Q. Inhibition of translation initiation factors might be the potential therapeutic targets for HCV patients with hepatic iron overload. Med Hypotheses 2012; 78: 142-143 [PMID: 22047986 DOI: 10.1016/ j.mehy.2011.10.011]
51. Liu H, Trinh TL, Dong H, Keith R, Nelson D, Liu C. Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus. PLoS One 2012; 7: e46631 [PMID: 23110054 DOI: 10.1371/journal.pone.0046631]
52. Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: 3782-3786 [PMID: 22876027 DOI: 10.3748/wjg.v18.i29.3782]
53. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77-85 [PMID: 21953442 DOI: 10.1002/hep.24706]
54. Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, Pulixi EA, Fracanzani AL, Fargion S. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One 2012; 7: e48804 [PMID: 23144979 DOI: 10.1371/journal.pone.0048804]
55. Deugnier YM, Charalambous P, Le Quilleuc D, Turlin B, Searle J, Brissot P, Powell LW, Halliday JW. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18: 1363-1369 [PMID: 7902316]
56. Jüngst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, Schramel P, Schirmacher P, Sauerbruch T, Caselmann WH. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology 2004; 39: 1663-1672 [PMID: 15185308]
57. Loeb LA, James EA, Waltersdorph AM, Klebanoff SJ. Mutagenesis by the autoxidation of iron with isolated DNA. Proc Natl Acad Sci USA 1988; 85: 3918-3922 [PMID: 2453880]
58. Meneghini R. Iron homeostasis, oxidative stress, and DNA damage. Free Radic Biol Med 1997; 23: 783-792 [PMID: 9296456]
59. Lawless MW, O'Byrne KJ, Gray SG. Targeting oxidative stress in cancer. Expert Opin Ther Targets 2010; 14: 1225-1245 [PMID: 20942747 DOI: 10.1517/14728222.2010.526933]
60. Lawless MW, Greene CM. Toll-like receptor signalling in liver disease: ER stress the missing link? Cytokine 2012; 59: 195-202 [PMID: 22579700 DOI: 10.1016/j.cyto.2012.04.003]
61. Romilda C, Marika P, Alessandro S, Enrico L, Marina B, Andromachi K, Umberto C, Giacomo Z, Claudia M, Massimo R, Fabio F. Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. BMC Cancer 2012; 12: 177 [PMID: 22587342 DOI: 10.1186/1471-2407-12-177]
62. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128 [PMID: 1937131]
63. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 1993; 57: 779S-785S; discussion 785S-786S [PMID: 8475896]
64. Cheeseman KH. Mechanisms and effects of lipid peroxidation. Mol Aspects Med 1993; 14: 191-197 [PMID: 8264333]
65. Cadenas E. Biochemistry of oxygen toxicity. Annu Rev Biochem 1989; 58: 79-110 [PMID: 2673022]
66. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002; 3: 420-425 [PMID: 11991946 DOI: 10.1093/embo-reports/ kvf094]
67. Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G. Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol 1979; 42: 345-353 [PMID: 157770]
68. Green R, Esparza I, Schreiber R. Iron inhibits the nonspecific tumoricidal activity of macrophages. A possible contributory mechanism for neoplasia in hemochromatosis. Ann N Y Acad Sci 1988; 526: 301-309 [PMID: 2455463]
69. Asare GA, Bronz M, Naidoo V, Kew MC. Interactions between aflatoxin B1 and dietary iron overload in hepatic mutagenesis. Toxicology 2007; 234: 157-166 [PMID: 17399882]
70. Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. p53 mutations in british patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology 1999; 117: 154-160 [PMID: 10381922]
71. Marrogi AJ, Khan MA, van Gijssel HE, Welsh JA, Rahim H, Demetris AJ, Kowdley KV, Hussain SP, Nair J, Bartsch H, Okby N, Poirier MC, Ishak KG, Harris CC. Oxidative stress and p53 mutations in the carcinogenesis of iron overloadassociated hepatocellular carcinoma. J Natl Cancer Inst 2001; 93: 1652-1655 [PMID: 11698570]
72. Hussain SP, Raja K, Amstad PA, Sawyer M, Trudel LJ, Wogan GN, Hofseth LJ, Shields PG, Billiar TR, Trautwein C, Hohler T, Galle PR, Phillips DH, Markin R, Marrogi AJ, Harris CC. Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci USA 2000; 97: 12770-12775 [PMID: 11050162]
73. Gouas DA, Shi H, Hautefeuille AH, Ortiz-Cuaran SL, Legros PC, Szymanska KJ, Galy O, Egevad LA, Abedi-Ardekani B, Wiman KG, Hantz O, Caron de Fromentel C, Chemin IA, Hainaut PL. Effects of the TP53 p. R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis 2010; 31: 1475-1482 [PMID; 20538734 DOI: 10.1093/carcin/bgq118]
74. Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci USA 1983; 80: 2258-2262 [PMID: 6300903]
75. Ohgami RS, Campagna DR, Greer EL, Antiochos B, Mc-Donald A, Chen J, Sharp JJ, Fujiwara Y, Barker JE, Fleming MD. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet 2005; 37: 1264-1269 [PMID: 16227996 DOI: 10.1038/ ng1658]
76. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 2008; 28: 197-213 [PMID: 18489257 DOI: 10.1146/annurev. nutr.28.061807.155521]
77. Magro G, Cataldo I, Amico P, Torrisi A, Vecchio GM, Parenti R, Asioli S, Recupero D, D'Agata V, Mucignat MT, Perris R. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid 2011; 21: 267-277 [PMID; 21323588 DOI: 10.1089/thy.2010.0173]
78. Kwok JC, Richardson DR. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 2002; 42: 65-78 [PMID: 11923069]
79. Rovera G, Santoli D, Damsky C. Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 1979; 76: 2779-2783 [PMID: 288066]
80. Castoldi M, Muckenthaler MU. Regulation of iron homeostasis by microRNAs. Cell Mol Life Sci 2012 Jun 9; Epub ahead of print [PMID: 22678662]
81. Schaar DG, Medina DJ, Moore DF, Strair RK, Ting Y. miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol 2009; 37: 245-255 [PMID; 19135902 DOI: 10.1016/j.exphem.2008.10.002]
82. Hubert N, Hentze MW. Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci USA 2002; 99: 12345-12350 [PMID: 12209011]
83. Gunshin H, Allerson CR, Polycarpou-Schwarz M, Rofts A, Rogers JT, Kishi F, Hentze MW, Rouault TA, Andrews NC, Hediger MA. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett 2001; 509: 309-316 [PMID: 11741608]
84. Tchernitchko D, Bourgeois M, Martin ME, Beaumont C. Expression of the two mRNA isoforms of the iron transporter Nramp2/DMTI in mice and function of the iron responsive element. Biochem J 2002; 363: 449-455 [PMID: 11964145]
85. Andolfo I, De Falco L, Asci R, Russo R, Colucci S, Gorrese M, Zollo M, Iolascon A. Regulation of divalent metal transporter 1 (DMT1) non-IRE isoform by the microRNA Let-7d in erythroid cells. Haematologica 2010; 95: 1244-1252 [PMID: 20410187]
86. Faller M, Matsunaga M, Yin S, Loo JA, Guo F. Heme is involved in microRNA processing. Nat Struct Mol Biol 2007; 14: 23-29 [PMID: 17159994]
87. Arosio P, Levi S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta 2010; 1800: 783-792 [PMID; 20176086 DOI: 10.1016/j.bbagen.2010.02.005]
88. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA, Pogribny IP. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 2011; 126: 63-71 [PMID: 20390345 DOI: 10.1007/ s10549-010-0849-4]
89. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603 [PMID: 19665978 DOI: 10.1016/ j.cell.2009.07.011]
90. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009; 4: e7181 [PMID: 19787069 DOI: 10.1371/journal.pone.0007181]
91. Castoldi M, Vujic Spasic M, Altamura S, Elmén J, Lindow M, Kiss J, Stolte J, Sparla R, D'Alessandro LA, Klingmüller U, Fleming RE, Longerich T, Gröne HJ, Benes V, Kauppinen S, Hentze MW, Muckenthaler MU. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 2011; 121: 1386-1396 [PMID: 21364282 DOI: 10.1172/JCI44883]
92. Bolondi G, Garuti C, Corradini E, Zoller H, Vogel W, Finkenstedt A, Babitt JL, Lin HY, Pietrangelo A. Altered hepatic BMP signaling pathway in human HFE hemochromatosis. Blood Cells Mol Dis 2010; 45: 308-312 [PMID: 20863724 DOI: 10.1016/j.bcmd.2010.08.010]
93. Jopling CL, Norman KL, Sarnow P. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb Symp Quant Biol 2006; 71: 369-376 [PMID: 17381319]
94. Jopling CL. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans 2008; 36: 1220-1223 [PMID; 19021529 DOI: 10.1042/BST0361220]
95. Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Med Wkly 2010; 140: 3-11 [PMID: 19950038]
96. Ryan JD, Altamura S, Devitt E, Mullins S, Lawless MW, Muckenthaler MU, Crowe J. Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology 2012; 56: 492-500 [PMID; 22334511 DOI: 10.1002/hep.25666]
97. Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, Mao TK, Coppel RL, Ansari AA, Gershwin ME. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009; 32: 246-253 [PMID: 19345069 DOI: 10.1016/j.jaut.2009.02.022]
98. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-678 [PMID: 16924677]
99. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648-656 [PMID: 18291553 DOI: 10.1016/j.jhep.2008.01.019]
100. Svasti S, Masaki S, Penglong T, Abe Y, Winichagoon P, Fucharoen S, Umemura T. Expression of microRNA-451 in normal and thalassemic erythropoiesis. Ann Hematol 2010; 89: 953-958 [PMID: 20461517 DOI: 10.1007/ s00277-010-0980-7]
101. Geekiyanage H, Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid β, novel targets in sporadic Alzheimer's disease. J Neurosci 2011; 31: 14820-14830 [PMID: 21994399 DOI: 10.1523/JNEUROSCI. 3883-11.2011]
102. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. FEBS J 2010; 277: 2015-2021 [PMID: 20412055 DOI: 10.1111/j.1742-4658.2010.07632.x]
103. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53: 209-218 [PMID: 20890893 DOI: 10.1002/hep.23922]
104. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845 [PMID: 20041405 DOI: 10.1002/hep.23380]
105. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
106. Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, Torok NJ, Wu J, Zern MA. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol 2010; 298: G101-G106 [PMID: 19892940 DOI: 10.1152/ajpgi.00220.2009]
107. Guo CJ, Pan Q, Jiang B, Chen GY, Li DG. Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis 2009; 14: 1331-1340 [PMID: 19784778 DOI: 10.1007/s10495-009-0401-3]
108. Guo CJ, Pan Q, Li DG, Sun H, Liu BW. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. J Hepatol 2009; 50: 766-778 [PMID: 19232449 DOI: 10.1016/j.jhep.2008.11.025]
109. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 2009; 583: 759-766 [PMID: 19185571 DOI: 10.1016/j.febslet.2009.01.034]
110. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138: 705-714, 714. e1-4 [PMID; 19843474 DOI: 10.1053/j.gastro.2009.10.002]
111. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-1017 [PMID; 19524505 DOI: 10.1016/j.cell.2009.04.021]
112. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761-5767 [PMID: 19584283 DOI: 10.1158/0008-5472. CAN-08-4797]
113. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099 [PMID: 17616664]
114. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526-3536 [PMID; 19617899 DOI: 10.1038/onc.2009.211]
115. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-32027 [PMID: 19726678 DOI: 10.1074/jbc. M109.016774]
116. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50: 113-121 [PMID: 19441017 DOI: 10.1002/hep.22919]
117. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumorsuppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-776 [PMID: 19843643 DOI: 10.1093/ carcin/bgp250]
118. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL, Linsley PS, Cleary MA. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008; 28: 2167-2174 [PMID: 18212054 DOI: 10.1128/MCB.01977-07]
119. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, Farace MG, Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26: 3699-3708 [PMID: 17627278]
120. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/ p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-5661 [PMID: 18521080 DOI: 10.1038/ onc.2008.178]
121. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010; 70: 5184-5193 [PMID: 20501828 DOI: 10.1158/0008-5472.CAN-10-0145]
122. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 264-269 [PMID: 20018759 DOI: 10.1073/pnas.0907904107]
123. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658 [PMID: 17681183]
124. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM. miR-221 and-222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16: 498-509 [PMID; 19962668 DOI: 10.1016/j.ccr.2009.10.014]
125. Lan FF, Wang H, Chen YC, Chan CY, Ng SS, Li K, Xie D, He ML, Lin MC, Kung HF. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). Int J Cancer 2011; 128: 319-331 [PMID: 20309945 DOI: 10.1002/ijc.25336]
126. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-843 [PMID: 15944709]
127. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K, Jacob ST. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68: 5049-5058 [PMID: 18593903 DOI: 10.1158/0008-5472.CAN-07-6655]
128. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hipposignaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010; 394: 623-627 [PMID: 20226166 DOI: 10.1016/j.bbrc.2010.03.036]
129. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ. MicroRNA-18a prevents estrogen receptoralpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009; 136: 683-693 [PMID; 19027010 DOI: 10.1053/j.gastro.2008.10.029]
130. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, Mac-Dougald OA, Cho KR, Fearon ER. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-1307 [PMID: 17656095]
131. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-752 [PMID: 17540599]
132. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-1134 [PMID: 17554337]
133. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-743 [PMID: 17540598]
134. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011; 104: 235-240 [PMID: 21102580 DOI: 10.1038/sj.bjc.6606010]
135. Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008; 375: 315-320 [PMID: 18692484 DOI: 10.1016/j.bbrc.2008.07.154]
136. Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, Tatsumi T, Ishida H, Noda T, Nagano H, Doki Y, Mori M, Hayashi N. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 2010; 52: 698-704 [PMID: 20347499 DOI: 10.1016/j.jhep.2009.12.024]
137. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-1142 [PMID: 19155302 DOI: 10.1158/0008-5472.CAN-08-2886]
138. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009; 15: 5073-5081 [PMID: 19671867 DOI: 10.1158/1078-0432. CCR-09-0092]
139. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009; 100: 1234-1242 [PMID; 19486339 DOI: 10.1111/j.1349-7006.2009.01164.x]
140. Yang L, Ma Z, Wang D, Zhao W, Chen L, Wang G. MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol Ther 2010; 9: 803-808 [PMID: 20364114]
141. Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010; 16: 867-875 [PMID; 20103675 DOI: 10.1158/1078-0432.CCR-09-1840]
142. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, Ghoshal K. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29: 1787-1797 [PMID: 20023698 DOI: 10.1038/onc.2009.468]
143. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009; 50: 490-499 [PMID: 19472311 DOI: 10.1002/hep.23008]
144. Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y, Sun S. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology 2010; 51: 1614-1623 [PMID: 20209605 DOI: 10.1002/hep.23566]
145. Ding J, Huang S, Wu S, Zhao Y, Liang L, Yan M, Ge C, Yao J, Chen T, Wan D, Wang H, Gu J, Yao M, Li J, Tu H, He X. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol 2010; 12: 390-399 [PMID: 20305651 DOI: 10.1038/ncb2039]
146. Yao J, Liang L, Huang S, Ding J, Tan N, Zhao Y, Yan M, Ge C, Zhang Z, Chen T, Wan D, Yao M, Li J, Gu J, He X. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 2010; 51: 846-856 [PMID: 20054866 DOI: 10.1002/hep.23443]
147. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49: 1571-1582 [PMID; 19296470 DOI: 10.1002/hep.22806]
148. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang ZY, Wang XW. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 2010; 52: 690-697 [PMID: 20338660 DOI: 10.1016/j.jhep.2009.12.025]
149. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009; 275: 44-53 [PMID: 19006648 DOI: 10.1016/ j.canlet.2008.09.035]
150. Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, Riva P, Portolani N, Giulini SM, De Petro G, Barlati S. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J 2009; 276: 2966-2982 [PMID: 19490101 DOI: 10.1111/j.1742-4658.2009.07014.x]
151. Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, Sun Z, Wei L, Zheng X. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2009; 49: 1194-1202 [PMID: 19133651 DOI: 10.1002/hep.22757]
152. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838 [PMID: 15944708]
153. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011; 406: 70-73 [PMID: 21295551 DOI: 10.1016/j.bbrc.2011.01.111]
154. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118 [PMID: 19362088 DOI: 10.1053/j.gastro.2009.04.005]
155. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-360 [PMID: 21278583 DOI: 10.1097/MCG.0b013e3181f18ac2]
156. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447 [PMID: 19812400 DOI: 10.1056/NEJMoa0901282]
157. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907 [PMID; 18176954 DOI: 10.1002/hep.22160]
158. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47: 1955-1963 [PMID: 18433021 DOI: 10.1002/ hep.22256]
159. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011; 140: 1618-1628. e16 [PMID: 21324318 DOI: 10.1053/ j.gastro.2011.02.009]
160. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201 [PMID; 19965718 DOI: 10.1126/science.1178178]
161. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci USA 2011; 108: 4991-4996 [PMID: 21383155 DOI: 10.1073/pnas.1016606108]
162. Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010; 51: 1494-1504 [PMID: 20127796 DOI: 10.1002/hep.23401]
163. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, Iliopoulos D. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011; 147: 1233-1247 [PMID: 22153071 DOI: 10.1016/j.cell.2011.10.043]
164. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 2012; 9: 703-719 [PMID: 22664915 DOI: 10.4161/rna.20481]
165. Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G, Yang Y, Wang RY, Yang S, Huo XS, Zhang L, Wang F, Sun SH, Zhou WP. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. Hepatology 2012; 56: 2231-2241 [PMID: 22706893 DOI: 10.1002/hep.25895]
166. Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J, Zhang Y, Chen J, Shen H, Hu Z. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PLoS One 2012; 7: e35145 [PMID: 22493738 DOI: 10.1371/journal.pone.0035145]
167. Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, Shang JL, Gao CF, Zhang FR, Wang F, Sun SH. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011; 54: 1679-1689 [PMID: 21769904 DOI: 10.1002/hep.24563]
168. Hauptman N, Glavač D. Long non-coding RNA in cancer. Int J Mol Sci 2013; 14: 4655-4669 [PMID: 23443164 DOI: 10.3390/ijms14034655]